Search

Displaying results 5081 - 5090 of 7897 in total
  1. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  2. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … with a possible increased risk of death outweighing the benefits.

  3. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  4. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  5. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  6. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

  7. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  8. Drug

    Ertapenem

    go.drugbank.com/drugs/DB00303
    ApprovedInvestigational

    [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. … Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.[L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.

    Products: ERTAPENEM 1G/VIAL POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE
  9. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia.

    Products: A. T. O. MEPIVACAINE 3% PLAIN. SOLUCION INYECTYABLE
  10. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.